Real-world multicentre cohort of first-line pembrolizumab alone or in combination with platinum-based chemotherapy in non-small cell lung cancer PD-L1 ≥ 50%

RT @PonsTostivint: Glad to share our real-world, multicentre study assessing the effectiveness of #immunotherapy 1L pembro alone or in comb…

RT @PonsTostivint: Glad to share our real-world, multicentre study assessing the effectiveness of #immunotherapy 1L pembro alone or in comb…

RT @JulienMazieres: Interesting to refer to the 2023 ESMO guidelines for 1L adv #NSCLC PS 0-1, PD-L1 ≥50%: Pembrolizumab standard 1L optio…

Interesting to refer to the 2023 ESMO guidelines for 1L adv #NSCLC PS 0-1, PD-L1 ≥50%: Pembrolizumab standard 1L option [I, A]. ChT-ICI is an option for pts with a need for a fast tumour load reduction [IV, B]. https://t.co/4LCNJm7lbS